Blood Platelet Disorders: Clinical Trials

257 trials for Blood Platelet Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

132 completed, 31 unknown, 30 recruiting, 29 terminated. 257 Phase 3, 35 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3257Completed 132, Unknown 31, Recruiting 30, Terminated 29, Active not recruiting 17, Withdrawn 10, Not yet recruiting 8
Phase 235Unknown 11, Completed 10, Terminated 5, Not yet recruiting 3, Recruiting 3, Active not recruiting 2, Withdrawn 1

Follow Blood Platelet Disorders: new trials by email Literature Review of Blood Platelet Disorders trials Research Report on Blood Platelet Disorders

Trials (filtered) newest first · largest first

All 257 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Evaluation of Sutacimig in Glanzmann Thrombasthenia
Sutacimig - Thrombasthenia
Phase 3RecruitingHemab ApS762026-10-272026-11-13
rhTPO for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Procedures.
rhTPO, Placebo - Thrombocytopenia Associated With Chronic Liver Disease
Phase 3RecruitingMIBIO PTE. LTD.1502026-10-202026-11-06
Hetrombopag for Thrombocytopenia in Patients Scheduled for Elective Hepatic Interventional Diagnostic and Therapeutic Procedures: A Clinical Study
Hetrombopag, Placebo - Thrombocytopenia, Hepatic Interventional Procedure
Phase 3Not yet recruitingZhongda Hospital1082026-10-152026-11-09
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
INCA033989, Best Available Treatment - Essential Thrombocythemia
Phase 3RecruitingIncyte Corporation4262026-09-082026-11-13
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
Romiplostim, Predniso(lo)ne - Primary Immune Thrombocytopenia
Phase 3RecruitingAmgen1262026-08-212026-09-17
Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP
Sirolimus (RAPAMUNE) - Kaposiform Hemangioendothelioma (KHE), Kasabach Merritt Phenomenon
Phase 2 / Phase 3RecruitingYi Ji762026-06-162026-06-18
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
Sirolimus, Placebo - Systemic Lupus Erythematosus, Immune Thrombocytopenia
Phase 2 / Phase 3RecruitingChinese SLE Treatment And Research Group1642026-06-072026-06-18
ATRA for Management of Primary ITP
all-trans retinoic acid (ATRA), Placebo - Immune Thrombocytopenia
Phase 3Not yet recruitingPeking University People's Hospital1922026-05-302026-05-19
Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
QL0911, Placebo - Thrombocytopenia, Immune
Phase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.602026-04-202026-03-06
High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia
High-Dose Dexamethasone Combined with Orelabrutinib, High-Dose Dexamethasone Combined with Placebo - Primary Immune Thrombocytopenia (ITP)
Phase 3RecruitingShandong University862026-04-082026-04-30
Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT
etamsylate, Placebo - Hematopoietic Stem Cell Transplantation, Thrombocytopenia
Phase 3RecruitingFirst Affiliated Hospital of Zhejiang University4042025-12-162026-03-02
Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
Avatrombopag+All trans retinoic acid, Avatrombopag - ITP - Immune Thrombocytopenia
Phase 2 / Phase 3Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2482025-12-012025-12-12
An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia
Human immunoglobulin (pH4) for intravenous injection - Primary Immune Thrombocytopenia (ITP)
Phase 3RecruitingGrand Shuyang Life Sciences (Chengdu) Co., Ltd.362025-11-242026-04-08
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
rilzabrutinib - Immune Thrombocytopenia
Phase 3RecruitingSanofi602025-10-242026-11-12
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Efgartigimod IV, Placebo IV - Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia
Phase 2 / Phase 3Recruitingargenx242025-10-202026-11-16
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
VGA039 - Von Willebrand Disease (VWD)
Phase 3RecruitingVega Therapeutics, Inc602025-10-152026-09-14
Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan
rilzabrutinib - Immune Thrombocytopenia
Phase 3Active not recruitingSanofi32025-10-152026-11-10
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
VONVENDI, ADVATE - Von Willebrand Disease (VWD)
Phase 3RecruitingTakeda202025-10-132026-01-08
The Holistic Study
Avatrombopag, Rituximab (Arm B) - Thrombocytopenia Purpura
Phase 3Not yet recruitingOstfold Hospital Trust2202025-09-152025-09-09
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Mezagitamab - Immune Thrombocytopenic Purpura (ITP)
Phase 3RecruitingTakeda1502025-08-142026-10-30

Showing 20 of 257. Sign in to see all of them.

Narrower conditions

Purpura, Thrombocytopenic, Idiopathic (120)  ·  Thrombocytopenia (70)  ·  Thrombocythemia, Essential (31)  ·  Primary Myelofibrosis (20)  ·  von Willebrand Diseases (19)  ·  Polycythemia Vera (18)  ·  Myeloproliferative Disorders (15)  ·  Leukemia, Myeloid, Acute (14)  ·  Blast Crisis (13)  ·  Hematologic Diseases (13)  ·  Leukemia, Myeloid, Accelerated Phase (13)  ·  Leukemia, Myeloid, Chronic-Phase (13)  ·  Lymphoma, Follicular (13)  ·  Lymphoma, Non-Hodgkin (13)  ·  Thrombotic Microangiopathies (13)

Broader conditions

Hemic and Lymphatic Diseases (256)  ·  Hematologic Diseases (244)  ·  Cytopenia (205)  ·  Blood Coagulation Disorders (183)  ·  Hemorrhagic Disorders (168)  ·  Pathological Conditions, Signs and Symptoms (161)  ·  Pathologic Processes (158)  ·  Signs and Symptoms (144)  ·  Thrombotic Microangiopathies (143)  ·  Immune System Diseases (140)  ·  Thrombocytopenia (135)  ·  Skin Manifestations (132)  ·  Hemorrhage (128)  ·  Purpura (122)

Interventions

eltrombopag (21)  ·  Dexamethasone (18)  ·  Rituximab (16)  ·  romiplostim (15)  ·  Immunoglobulins, Intravenous (14)  ·  avatrombopag (12)  ·  Factor VIII (10)  ·  Thrombopoietin (10)  ·  Prednisone (8)  ·  anagrelide (7)  ·  Prednisolone (6)  ·  ravulizumab (6)  ·  Hydroxyurea (5)  ·  Standard of Care (5)  ·  von Willebrand Factor (5)

Sponsors

Shandong University (18)  ·  Amgen (10)  ·  Novartis Pharmaceuticals (8)  ·  Assistance Publique - Hôpitaux de Paris (7)  ·  argenx (7)  ·  Baxalta now part of Shire (6)  ·  GlaxoSmithKline (6)  ·  Takeda (6)  ·  Alexion Pharmaceuticals, Inc. (5)  ·  Octapharma (5)  ·  Peking University People's Hospital (5)  ·  Sanofi (5)  ·  Sobi, Inc. (5)  ·  The First Affiliated Hospital of Soochow University (5)  ·  AOP Orphan Pharmaceuticals AG (4)

Countries

United States (105)  ·  China (73)  ·  France (63)  ·  Italy (63)  ·  United Kingdom (59)  ·  Spain (56)  ·  Germany (55)  ·  Poland (49)  ·  Japan (42)  ·  Canada (41)  ·  Russia (39)  ·  Australia (34)  ·  Czechia (33)  ·  Austria (32)  ·  Hungary (32)

Top investigators

Ming Hou, Dr (5)  ·  Ming Hou, Dr. (4)  ·  James George, MD (3)  ·  Charlotte Bradbury (2)  ·  Cindy Leissinger, MD (2)

Results publications

PMID 19005182, PMID 19671919, PMID 33783815, PMID 33995988, PMID 34219224, PMID 40277027, PMID 12944568, PMID 17077333, PMID 18242413, PMID 19846889, PMID 21533818, PMID 22117897, PMID 22494019, PMID 25566808, PMID 29778606, PMID 32047671, PMID 33275766, PMID 11824975, PMID 12966125, PMID 15459300, PMID 15803929, PMID 17397698, PMID 18510702, PMID 19109560, PMID 19635187, PMID 19731307, PMID 20130241, PMID 20164484, PMID 20841509, PMID 20863431, PMID 21266777, PMID 21325604, PMID 21503695, PMID 21713321, PMID 22409309, PMID 22480131, PMID 22496156, PMID 22538854, PMID 22871490, PMID 22913681, PMID 23169778, PMID 23278371, PMID 23293082, PMID 23315161, PMID 2334081, PMID 23462431, PMID 23492914, PMID 23753021, PMID 23896965, PMID 24254965

NIH funding

2023 (12), 2016 (5), 2019 (5), 2009 (4), 2014 (3), 2017 (3), U01HL072268 (3), 2025 (2), 2004 (1), 2008 (1), 2015 (1), 2018 (1), P01CA108671 (1), P30CA068485 (1), R01CA127655 (1)